体内
体外
嵌合抗原受体
癌症研究
癌症免疫疗法
细胞毒性T细胞
药物输送
化学
材料科学
免疫疗法
生物物理学
纳米技术
免疫系统
生物化学
生物
免疫学
生物技术
作者
Gloria B. Kim,Virginia Aragon‐Sanabria,Lauren N. Randolph,Hali Jiang,Joshua Reynolds,Becky Webb,Achuthamangalam B. Madhankumar,Xiaojun Lian,James R. Connor,Jian Yang,Cheng Dong
标识
DOI:10.1016/j.bioactmat.2020.04.011
摘要
Glioblastoma (GBM), the deadliest form of brain cancer, presents long-standing problems due to its localization. Chimeric antigen receptor (CAR) T cell immunotherapy has emerged as a powerful strategy to treat cancer. IL-13-receptor-α2 (IL13Rα2), present in over 75% of GBMs, has been recognized as an attractive candidate for anti-glioblastoma therapy. Here, we propose a novel multidisciplinary approach to target brain tumors using a combination of fluorescent, therapeutic nanoparticles and CAR T cells modified with a targeted-quadruple-mutant of IL13 (TQM-13) shown to have high binding affinity to IL13Rα2-expressing glioblastoma cells with low off-target toxicity. Azide-alkyne cycloaddition conjugation of nanoparticles to the surface of T cells allowed a facile, selective, and high-yielding clicking of the nanoparticles. Nanoparticles clicked onto T cells were retained for at least 8 days showing that the linkage is stable and promising a suitable time window for
科研通智能强力驱动
Strongly Powered by AbleSci AI